Effect of Proton Pump Inhibitor of Daily Use for One Month on Kidney Function Test

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04022837

Enrollment

200

Registered

2019-07-17

Start date

2019-11-01

Completion date

2021-12-31

Last updated

2019-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proton Pump Inhibitor Allergy

Brief summary

The aim of this study to: evaluate the association between prolonged use of PPI and adverse renal outcomes on patients with normal renal function and others with abnormal renal function

Detailed description

Proton pump inhibitors (PPIs) are one of the most widely used classes of drugs and are prescribed primarily for gastric acid-related diseases, eradication of Helicobacter pylori, and prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy,and gastroesophagial reflux diseases , Although PPIs have an excellent overall safety profile, some severe adverse effects, which include bone fracture, dementia, myocardial infarction, infections, micronutrient deficiencies, and kidney diseases, PPIs may trigger acute interstitial nephritis,a potentially sever adverse event commonly associated with acute kidney injury. The increase in prescription and inadequate use of this class of medication calls for studies on the effects of prolonged PPI therapy on renal function.

Interventions

DRUGPantoprazole 40mg

effect of this drug on renal function

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* patients with peptic ulcer disease or gastroesophagial reflux with normal l renal function * patients with peptic ulcer disease or gastroeosophagial reflux with abnormal renal function

Exclusion criteria

* 1- cigarette smoker: Cigarette smoking status was defined categorically as current,former, or never smoker at baseline. 2-biabetic patients: diabetes mellitus is defined by a fasting blood glucose concentration \>\_ 126 mg/dl ,random glucose level of \>200 mg 3-patients take corticosteroid 4-patients with hypersensitivity to these drugs

Design outcomes

Primary

Measure	Time frame	Description
kidney function	one month	eGFR=175xage(y/0)x\^(-0.203)xplasma creatinine (mg/dl)x\^(-1.154)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026